RxDoctor Payments Data

Dana Anctil

Adult Health · Clermont, FLNPI 1851896872

Payments from drug & device makers

$2,146in general payments, 2019–2025

Across 47 payments — averaging $45.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cvrx, Inc.$970
  • AstraZeneca$211
  • Kestra Medical Technology Services, Inc.$178
  • Abiomed$161
  • Merck$126
  • Impulse Dynamics (USA) Inc.$100
  • plus $399 from 10 others

What the payments were for

  • Travel & lodging$35417%
  • Food & beverage$1,59975%
  • Education$653%
  • Gifts$1286%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,146 in reported general payments places this provider in the 75th percentile of 2,237 adult health providers in Florida.

See all adult health providers in Florida

Medicare billing

Part B allowed, 2024
$37,297
Medicare patients
189
Services billed
362

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin345$287,752
FarxigaDapagliflozin Propanediol245$186,221
EntrestoSacubitril/Valsartan123$124,590
EliquisApixaban90$92,489
XareltoRivaroxaban16$19,935
Torsemide233$4,897
Amiodarone Hcl21$2,835
Metoprolol Succinate203$2,625
Spironolactone244$1,462
Eplerenone12$1,342
Bumetanide38$1,157
Potassium Chloride41$1,153
Furosemide149$641
Losartan Potassium77$568
Carvedilol59$520

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$211$186,221245 claims
NovartisEntresto$18$124,590123 claims
PfizerEliquis$80$92,48990 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,237 adult health providers in Florida.

Other adult health in Clermont

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →